Drug Combination Details
| General Information of the Combination (ID: C82826) | |||||
|---|---|---|---|---|---|
| Name | Hesperetin NP Info | + | Etoposide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2 phase | ||||
| In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
| Experimental
Result(s) |
Hesperetin combined with etoposide showed additive effects on the inhibition of cell growth. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Hesperetin-etoposide combinations induce cytotoxicity in U2OS cells: Implications on therapeutic developments for osteosarcoma. DNA Repair (Amst). 2017 Feb;50:36-42. | |||
